Overview

A Study of Macupatide (LY3532226) and Eloralintide (LY3841136), Alone or in Combination, in Adults With Obesity or Overweight and With Type 2 Diabetes

Status:
NOT_YET_RECRUITING
Trial end date:
2027-05-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to investigate weight reduction with macupatide and eloralintide, alone or in combination, in adult participants with obesity or overweight and with type 2 diabetes. Participation in the study will last about 48 weeks.
Phase:
PHASE2
Details
Lead Sponsor:
Eli Lilly and Company